168 related articles for article (PubMed ID: 31111279)
1. A Granular Approach to a Patient with Diarrhea and Flushing.
Gremida A; Mir F; McCarthy D
Dig Dis Sci; 2019 Jul; 64(7):1792-1797. PubMed ID: 31111279
[No Abstract] [Full Text] [Related]
2. Interactive medical case. A rash hypothesis.
Ross JJ; Saavedra A; Vleugels RA; Liu A; Castells MC
N Engl J Med; 2010 Jun; 362(24):e69. PubMed ID: 20560180
[No Abstract] [Full Text] [Related]
3. [Systemic mastocytosis].
Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
[TBL] [Abstract][Full Text] [Related]
4. Aggressive systemic mastocytosis mimicking sclerosing cholangitis.
Marbello L; Anghilieri M; Nosari A; Minola E; Cairoli R; Ricci F; Morra E
Haematologica; 2004 Sep; 89(9):ECR35. PubMed ID: 15377487
[TBL] [Abstract][Full Text] [Related]
5. [Vulvar oedema revealing systemic mastocytosis].
Deveza E; Locatelli F; Girardin M; Valmary-Degano S; Daguindau E; Aubin F; Humbert P; Pelletier F
Ann Dermatol Venereol; 2015 Nov; 142(11):685-9. PubMed ID: 26003033
[TBL] [Abstract][Full Text] [Related]
6. Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea.
Jakate S; Demeo M; John R; Tobin M; Keshavarzian A
Arch Pathol Lab Med; 2006 Mar; 130(3):362-7. PubMed ID: 16519565
[TBL] [Abstract][Full Text] [Related]
7. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
8. Presentation of untreated systemic mastocytosis as recurrent, pulseless-electrical-activity cardiac arrests resistant to cardiac pacemaker.
Butterfield JH; Weiler CR
Int Arch Allergy Immunol; 2014; 163(2):130-4. PubMed ID: 24335343
[TBL] [Abstract][Full Text] [Related]
9. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment options for mast cell activation disease.
Molderings GJ; Haenisch B; Brettner S; Homann J; Menzen M; Dumoulin FL; Panse J; Butterfield J; Afrin LB
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):671-94. PubMed ID: 27132234
[TBL] [Abstract][Full Text] [Related]
11. Recurrent syncope and anaphylaxis as presentation of systemic mastocytosis in a pediatric patient: case report and literature review.
Shaffer HC; Parsons DJ; Peden DB; Morrell D
J Am Acad Dermatol; 2006 May; 54(5 Suppl):S210-3. PubMed ID: 16631942
[TBL] [Abstract][Full Text] [Related]
12. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
13. Midostaurin: a magic bullet that blocks mast cell expansion and activation.
Valent P; Akin C; Hartmann K; George TI; Sotlar K; Peter B; Gleixner KV; Blatt K; Sperr WR; Manley PW; Hermine O; Kluin-Nelemans HC; Arock M; Horny HP; Reiter A; Gotlib J
Ann Oncol; 2017 Oct; 28(10):2367-2376. PubMed ID: 28945834
[TBL] [Abstract][Full Text] [Related]
14. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients.
Doyle LA; Sepehr GJ; Hamilton MJ; Akin C; Castells MC; Hornick JL
Am J Surg Pathol; 2014 Jun; 38(6):832-43. PubMed ID: 24618605
[TBL] [Abstract][Full Text] [Related]
15. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
[TBL] [Abstract][Full Text] [Related]
16. Burning mouth syndrome and mast cell activation disorder.
Afrin LB
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Apr; 111(4):465-72. PubMed ID: 21420635
[TBL] [Abstract][Full Text] [Related]
17. Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics.
Molderings GJ; Solleder G; Kolck UW; Homann J; Schröder D; von Kügelgen I; Vorreuther R
Urol Res; 2009 Aug; 37(4):227-9. PubMed ID: 19513706
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
[TBL] [Abstract][Full Text] [Related]
20. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
